15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering ADMA Biologics Inc, 2 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $17.00 to $18.00, so the covering firms are broadly aligned. The average target of $17.50 sits 106% above the current $8.48. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees revenue growth near 12% this year and 27% next, consensus EPS building from about $0.20 next quarter toward $0.98 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy267%
Hold133%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to ADMA Biologics Inc.
As of Jul, 2 of 3 firms rate ADMA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ADMA EPS & revenue forecast
EPS · NEXT QUARTER
$0.20
Range $0.18 – $0.21 · 3 analysts · +24% YoY
Next period, 3 analysts expect ADMA Biologics Inc to earn $0.20 a share (range $0.18 – $0.21), versus $0.16 a year earlier. Full-year consensus is $0.80, growing to $0.98 the year after.
REVENUE · NEXT QUARTER
$138.9M
Range $137.3M – $139.8M · 3 analysts · +9% YoY
Revenue is expected to reach $138.9M (range $137.3M – $139.8M), +9.0% year-over-year. Full-year consensus is $534.3M, rising to $700.6M next year.
Top analysts covering ADMA Biologics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ADMA.
#1
Kristen Kluska
Cantor Fitzgerald · Rank #162
Hold
No targeton ADMA
Overall win rate
38%
+ Follow
#2
Elliot Wilbur
Raymond James · Rank #234
Buy
$32.00+277.1% to target
Overall win rate
32%
+ Follow
#3
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$26.00+206.4% to target
Overall win rate
37%
+ Follow
#4
Anthony Petrone
Mizuho
Buy
$17.00+100.4% to target
Coverage
—
+ Follow
#5
GN
Gary Nachman
Canaccord Genuity
Buy
$18.00+112.1% to target
Coverage
—
+ Follow
ADMA stock forecast FAQ
What is ADMA's average 12-month price target?+
The 2 analysts with a live target average $17.50 for ADMA Biologics Inc over the next 12 months, ranging from a $18.00 high to a $17.00 low.
Is ADMA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 2 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ADMA?+
The Street-high target is $18.00 (Canaccord Genuity), and the Street-low is $17.00 (Mizuho). The average of all 2 active targets is $17.50.
How many Wall Street analysts cover ADMA?+
3 analysts have an active rating on ADMA Biologics Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering ADMA?+
Among analysts who currently cover ADMA, Kristen Kluska of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #162). Their current call is Hold.
What is ADMA Biologics Inc's projected EPS for next quarter?+
The consensus estimate is $0.20 per share (range $0.18 – $0.21) across 3 analysts. Full-year EPS is projected at $0.80, rising to $0.98 the following year.
How much revenue is ADMA Biologics Inc expected to report next quarter?+
Consensus revenue is $138.9M (range $137.3M – $139.8M). Full-year revenue is projected at $534.3M, growing to $700.6M next year.
Have analysts been upgrading or downgrading ADMA lately?+
As of Jul, 2 of 3 firms rate ADMA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ADMA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
